6
SENDERRA
Specialty Pharmacy

Name:

Street:

Phone:

Leqselvi™ Litfulo®

Olumiant®

Opzelura®

Otezla®

Sotyktu™

Vtama®

assistance founda Prescriber

PREVIOUS THERAPIES:

3712 E. Plano Parkway, Ste. 200 Plano, TX 75074

This prescription form is to be sent & received via fax

Dermatology Oral/Topical Enrollment Form

Physician Offices Call: 855-460-7928

Fax: 888-777-5645

Alt. Phone:

Has the patient received a loading dose/starter kit? ☐Yes Start Date

8 mg Tablet

50 mg Capsule

□<sub>2 mg Tablet</sub>

□4 mg Tablet

1.5 % Cream 60 gm

☐ 30 mg Tablet

1% Cream 60 gm

\*\*\*PLEASE FAX COPY OF PRESCRIPTION/MEDICAL CA

Tried & Failed (Duration):

6 mg Tablet

☐ 28 Day Starter Pack

ted from	a prescriber. Patien	its must bring an origi	nal prescription to	o the pharmacy, and ca	annot fax these	e referral for	ms to Senderra.	
natology		Prescriber:				NPI:		
/Topic ollmen	aı t Form	Supervising P	nysician:			NPI:		
sician Offices Call: 460-7928		Address:				Tax ID:		
		Phone: Fax:						
888-7	77-5645	Contact:						
		PATIENT INFO		DOD:		00		
		Trans M 🗖 Trans	F Other	DOB:/	_/	SS	:#: <del></del>	
	City:		State:			ZIP:		
ne:		☐ English	Spanish	Other:		Wt.:	Ht.:	
		PRESCRIF	TION					
kit?	Yes Start Date:		_ □ <sub>No</sub>   SH	IIP TO: Patient's	s Home 🗆	Ooctor's C	Office Other:	
			Directions	& Quantity				Refills
☐ <sub>Tak</sub>	e 8 mg PO twice	daily (Quantity: 60	)					
☐ <sub>Tak</sub>	e 50 mg PO once	daily (Quantity: 2	3)					
☐ Take 2 mg PO once daily (Quantity: 30)								
☐ Take 4 mg PO once daily (Quantity: 30)								
☐ Apply a thin layer to affected area(s) twice a day (Quantity: 1 tube)								
☐ Take as directed per package instructions (Quantity: 55)								
☐ Take 30 mg PO twice daily (Quantity: 60)								
□ <sub>Tak</sub>	e 6 mg PO once	daily (Quantity: 30	)					
□ <sub>App</sub>	oly a thin layer to a	affected area(s) or	ce a day (Qua	ntity: 1 tube)				
		MEDICAL INFO	RMATION					
				L AS ANY CLINIC	AL NOTES I	REGARDI	NG THERAPY**	**
(Durat	ion): Not i	「olerated: □	Contraind	ication:		<i>{</i> }	5 }	
	)	Ц				(And)		
	)					//\^\\\\	\	
	)				4	6 ( ) (		
	)						\	
	,	П				10/	MM	

	⊔ (	) 📙		
☐ Soriatane		) 🔲		
☐ Clobetasol		_) 🗆		
☐ Stelara		_) 🗆		\-\-\-\\\\
□ <sub>Humira</sub>		)		)
☐ Enbrel		_) 🗆		Affected Areas
□		_) 🗆		☐ Face ☐ Feet ☐ Groin ☐ Hands
PHOTOTHERAPY	Tried & Failed (Duration	on): Not Tolerated:	Contraindication:	□ Nails □ Scalp □ Other:
□ <sub>UVA /UVB</sub>		_) 🗆		PASI Score: BSA % SALT Score:
☐Patient cannot afford	☐ Photosensitivity	☐Risk of Skin Cancer	☐ Distance from Office	Date of Diagnosis:/
L20.9 Atopic Dermatitis		L40.0 Psoriasis Vulgari	s (Plaque Psoriasis)	Allergies:
☐ L63.9 Alopecia areata, unsp	pecified	L80 Vitiligo		
Other:				
Active TB ruled out: TYes		Hep B ruled out/treated:	□ <sub>Yes</sub> □ <sub>No Date:</sub> /_/	
Additional Clinical Information	on:			

American Academy of Dermatology Consensus Statement on Psoriasis Therapies Psoriasis is covering greater than 10% of body surface area Psoriasis is on palms, soles, head and neck, or genitalia Psoriasis occurs in conjunction with pain, swelling, or stiffness in joints Psoriasis patient needs more aggressive therapy due to impact on ability to perform daily activities, employment or interpersonal relationships PRESCRIBER SIGNATURE To Prescriber By signing this form and utilizing our services, you are also authorizing Senderra to serve as your prior authorization designated agent in dealing with medical and prescription insurance companies, and co-pay

**CONFIDENTIALITY NOTICE IMPORTANT:** This fax is intended to be delivered only to the named addressee. It contains material that is confidential, proprietary or exempt from disclosure under applicable law. If you are not the named addressee, you should not disseminate, distribute, or copy this fax. Please notify the sender immediately if you have received this document in error and then destroy this document immediately.